je.st
news
Gilead lifted by $3.6B 1Q sales of newest hepatitis C pill
2015-05-01 02:36:04| Biotech - Topix.net
Gilead Sciences raked in $3.6 billion from sales of its newest hepatitis C pill, lifting the drugmaker's results past Wall Street expectations. Meanwhile, sales of Gilead's previous hepatitis C drug, Sovaldi, dropped 57 percent to $972 million.
Tags: c
sales
newest
pill
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||